A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer

Trial Profile

A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 Sep 2017 According to a U. S. Food and Drug Administration media release, The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer.
    • 07 Jun 2017 According to an Amgen media release, the US FDA will review data supporting the BLA for ABP 215 on July 13, 2017. The FDA has set a Biosimilar User Fee Act (BsUFA) target action date of September 14, 2017, for ABP 215.
    • 02 Jun 2017 Results assessing the pharmacokinetics, clinical efficacy, safety, and immunogenicity of ABP 215 and bevacizumab in patients with advanced non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top